These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25521354)

  • 1. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
    Tay-Sontheimer J; Shireman LM; Beyer RP; Senn T; Witten D; Pearce RE; Gaedigk A; Gana Fomban CL; Lutz JD; Isoherranen N; Thummel KE; Fiehn O; Leeder JS; Lin YS
    Pharmacogenomics; 2014 Dec; 15(16):1947-62. PubMed ID: 25521354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
    Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
    J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
    Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
    Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
    Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
    Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
    Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
    Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 phenotyping with dextromethorphan.
    Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
    Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.
    Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Shirey CS; Gotschall R; Gaedigk A; Bertino JS
    Pharmacogenetics; 1998 Oct; 8(5):403-10. PubMed ID: 9825832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CYP2D6 activity by bupropion.
    Kotlyar M; Brauer LH; Tracy TS; Hatsukami DK; Harris J; Bronars CA; Adson DE
    J Clin Psychopharmacol; 2005 Jun; 25(3):226-9. PubMed ID: 15876900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of black seed on dextromethorphan O- and N-demethylation in human liver microsomes and healthy human subjects.
    Al-Jenoobi FI; Al-Thukair AA; Abbas FA; Ansari MJ; Alkharfy KM; Al-Mohizea AM; Al-Suwayeh SA; Jamil S
    Drug Metab Lett; 2010 Jan; 4(1):51-5. PubMed ID: 20201775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.